CD4+ CD25+ 调节性T细胞与自身免疫性甲状腺疾病

CD4+ CD25+ 调节性T细胞为新近发现的一群功能成熟的T细胞亚群.其特征性表达叉头盒蛋白3(Foxp3)分子,专职免疫无能和免疫抑制,在维持外周免疫耐受,防止自身免疫性疾病发病中起着极为关键的作用.CD4+ CD25+ 调节性T细胞在自身免疫性甲状腺疾病(AITD)发病中的作用引起了人们的关注.动物实验发现CD4+ CD25+ 调节性T细胞存在与否决定了实验动物是否发生实验性自身免疫性甲状腺炎(EAT)和Graves病.人体研究发现CD4+ CD25+ 调节性T细胞数目和功能异常与人AITD发生密切相关.这些研究结果提示,CD4+ CD25+ 调节性T细胞可能在AITD发病中起重要作用.     

CD4+CD25+调节性T细胞与支气管哮喘

支气管哮喘是一种常见的慢性呼吸道疾病,其免疫发病机制尚不十分清楚。CD4 CD25 调节性T细胞是一种特殊的调节性T细胞,参与自身免疫调节,维持自身免疫耐受。本文就CD4 CD25 调节性T细胞的特性及与支气管哮喘的发病机制、治疗、预后的研究进展做一综述。     

CD4+CD25+调节性T细胞在支气管哮喘中的研究进展

CD4 CD25 调节性T细胞(CD4 CD25 Treg)是一种表型和功能特异的T细胞亚群,它在抑制自身免疫性疾病的发生,诱导机体免疫耐受机制中发挥着重要作用。研究CD4 CD25 Treg在支气管哮喘中的功能机制,对阐明哮喘的发病机制及探索疾病免疫治疗方面有重要意义。     

CD4~+CD25~+Treg细胞在慢性乙型肝炎发病机制中的作用研究进展

CD4+CD25+调节性T细胞(CD4+CD25+Treg)是一个具有独特免疫调节功能的T细胞亚群,对维持机体免疫动态平衡具有重要作用。它不仅诱导产生自身免疫耐受,防止自身免疫性疾病的发生,而且能够限制免疫防御中T细胞和B细胞的过度活化,避免造成组织损伤。慢性乙型肝炎患者病毒感染的持续原因可能与体内CD4+CD25+Treg细胞数量或者功能异常,从而降低了机体对HBV发挥特异性效应的CD8+T细胞反应有关。     

外周血CD4+CD25+调节性T细胞在Graves病发病中的作用

测定不同阶段Graves病患者外周血中淋巴细胞亚群含量及CD4+ CD25+调节性T细胞功能.结果显示CD4+ CD25+调节性T细胞免疫功能减弱导致CD4+T细胞增殖失控可能是Graves病发病的重要原因,药物治愈患者其免疫功能难以完全恢复正常导致Grares病容易复发.     

FOXP3在系统性红斑狼疮患者CD4+CD25+调节性T细胞中的表达

目的 研究FOXP3在系统性红斑狼疮(SLE)患者的CD4+CD25调节性T细胞中的表达.方法 流式细胞仪检测CD4+CD25+,CD4+CD25bright T细胞中FOXP3蛋白的表达.利用免疫磁珠细胞分选法(MACS)分选出CD4+CD25+调节性T细胞,实时定量聚合酶链反应(real-time PCR)检测FOXP3基因的表达.结果 以FOXP3作为CD4+CD25+调节性T细胞的主要识别标志,初发、活动性SLE患者的CD4+CD25+ FOXP3+调节性T细胞在CD4+T细胞中的比例高于健康对照组[(9.1±0.7)%VS(4.8±0.4)%,P＜0.01],与SLEDAI评分呈明显正相关.CD4+CD25+调节性T细胞中FOXP3在蛋白和mRNA水平上的表达,SLE患者与健康对照组相比无明显差异.结论 SLE患者CD4+CD25+调节性T细胞中FOXP3的表达无明显异常,其CD4+T细胞中调节性T细胞的比例高于健康对照组.提示研究这类细胞在SLE发病中的作用应更关注其功能.     

CD4~+CD25~+Treg细胞在急性胰腺炎中作用的研究进展

CD4+CD25+调节性T细胞(Regulatory T cell,CD4+CD25+Treg)是具有负向免疫调节作用的CD4+T淋巴细胞亚群,现认为其在控制自身免疫性疾病的进展、抑制潜在有害的炎性反应及维持免疫稳态等方面起着关键性作用。急性胰腺炎(AP)是临床上常见的急腹症之一,大量研究证实,CD4+CD25+Treg细胞对AP的发病机制具有重要意义,此文就该方面研究进展进行综述。     

CD4+CD25+调节性T细胞在感染性疾病中的研究意义

免疫抑制是维持机体有效免疫应答的重要组成部分,近来研究认为CD4+CD25+调节性T细胞是免疫抑制机制中的关键成分.对该类细胞的研究多集中在自身免疫病、移植免疫、免疫耐受等方面.CD4+CD25+调节性T细胞的异常也涉及多种感染性疾病的进展,本文就其在感染性疾病中的研究意义作一综述.     

CD4+CD25+调节性T细胞及其分子标记物与支气管哮喘

CD4+CD25+调节性T细胞是一类以免疫抑制和免疫无能为特征的淋巴细胞群,FOXP3是CD4+CD25+调节性T细胞一个特征性的分子标志物,并且对CD4+CD25+调节性T细胞的发育、外周表达和功能维持有着关键性的作用.近年来,多项研究显示CD4+CD25+调节性T细胞参与并影响了支气管哮喘的发生、发展过程,对调节性T细胞或其相关基因的干预也许会成为支气管哮喘治疗的新方向.     

CD4+CD25+调节性T细胞在肿瘤免疫逃逸机制中的作用研究进展

CD4+CD25+调节性T细胞是一类具有免疫抑制功能的T细胞亚群,能阻止肿瘤免疫和逃避肿瘤对抗原的有效识别.Foxp3是近年来发现的一种转录因子,是CD4+CD25+调节性T细胞表面特异性标志,检测其表达可以作为判定CD4+CD25+调节性T细胞的方法.最近,大量研究已经证实CD4+CD25+调节性T细胞与各种肿瘤生存期和不良预后密切相关.目前,CD4+CD25+调节性T细胞的靶向治疗和选择性清除成为新的免疫治疗方法.     

Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes

CD8+CD25+ cells, which expressed high levels of Foxp3, glucocorticoid-induced tumor necrosis factor receptor (GITR), CCR8, tumor necrosis factor receptor 2 (TNFR2), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) mRNAs, were identified in the fibrous septa and medullary areas of human thymus. Activated CD8+CD25+ thymocytes did not produce cytokines, but most of them expressed surface CTLA-4 and transforming growth factor beta1 (TGF-beta1). Like CD4+CD25+, CD8+CD25+ thymocytes suppressed the proliferation of autologous CD25-T cells via a contact-dependent mechanism. The suppressive activity of CD8+CD25+ thymocytes was abrogated by a mixture of anti-CTLA-4 and anti-TGF-beta1 antibodies and it was mediated by their ability to inhibit the expression of the interleukin 2 receptor alpha chain on target T cells. These results demonstrate the existence of a subset of human CD8+CD25+ thymocytes sharing phenotype, functional features, and mechanism of action with CD4+CD25+ T regulatory cells.     

非小细胞肺癌患者CD3+、CD4+、CD8+、CD44+表达的临床研究

目的研究非小细胞肺癌患者外周血淋巴细胞中CD3+、CD4+、CD8+、CD4+4的表达水平。方法取65例非小细胞肺癌患者及22例健康正常人外周静脉血,应用流式细胞仪检验非小细胞肺癌患者(实验组)与健康人外周血淋巴细胞中(对照组)CD3+、CD4+、CD8+、CD4+4的表达水平。结果实验组与对照组CD3+、CD3+CD4+、CD3+CD8+、CD4+4在淋巴细胞中的比例存在显著性差异(P<0.05),其中,实验组占总淋巴细胞的比例分别为48.07±10.33%、30.93±6.68%、17.13±3.37%、55.45±4.35%;对照组CD3+、CD3+CD4+、CD3+CD8+、CD4+4占总淋巴细胞的比例分别为58.83±10.88%、34.89±6.45%、23.91±4.42%、62.85±7.56%;但鳞癌与腺癌组CD4+4的表达无显著性差异(P>0.05),其中,鳞癌组CD4+4所占比例为61.32±8.06%,腺癌组为64.43±6.76%。结论非小细胞肺癌患者外周血T细胞亚群及CD4+4的表达水平较正常组均低,其表达水平与组织类型无关。     

Decrease in CD4+CD25+ and CD8+CD28+ T cells in interstitial pneumonitis associated with rheumatic disease

The expression of CD25 or CD28 on T cells was examined in patients with rheumatic diseases associated with interstitial pneumonitis (IP), in order to investigate the conditions of CD4⁺CD25⁺ regulatory T cells and CD8⁺CD28⁻ suppressor T cells. Fifty-five patients with various rheumatic diseases and 23 normal controls were enrolled. CD4⁺CD25⁺ T cells of patients with IP were significantly decreased in comparison with non-IP patients, and the ratio of CD8⁺CD28⁻ T cells in patients with IP was significantly higher than that in non-IP patients or normal controls. These results for CD8⁺CD28⁻ T cells were in accord with the decrease in CD8⁺CD28⁺ T cells, and may be related to activation-induced CD8⁺CD28⁺ T-cell death. Thus, the abnormality of CD4⁺CD25⁺ regulatory T cells may be related to the pathogenesis of IP, and the survival and activation of CD8⁺ T cells.     

Decrease in CD4+CD25+ and CD8+CD28+ T cells in interstitial pneumonitis associated with rheumatic disease

Abstract

The expression of CD25 or CD28 on T cells was examined in patients with rheumatic diseases associated with interstitial pneumonitis (IP), in order to investigate the conditions of CD4⁺CD25⁺ regulatory T cells and CD8⁺CD28^? suppressor T cells. Fifty-five patients with various rheumatic diseases and 23 normal controls were enrolled. CD4⁺CD25⁺ T cells of patients with IP were significantly decreased in comparison with non-IP patients, and the ratio of CD8⁺CD28^? T cells in patients with IP was significantly higher than that in non-IP patients or normal controls. These results for CD8⁺CD28^? T cells were in accord with the decrease in CD8⁺CD28⁺ T cells, and may be related to activation-induced CD8⁺CD28⁺ T-cell death. Thus, the abnormality of CD4⁺CD25⁺ regulatory T cells may be related to the pathogenesis of IP, and the survival and activation of CD8⁺ T cells.     

CD19+CD5+ cells as indicators of preeclampsia

Preeclampsia is a devastating pregnancy-associated disorder affecting 5% to 8% of pregnant women worldwide. It emerges as an autoimmune-driven disease, and, among others, the autoantibodies against angiotensin type 1 receptor II have been proposed to account for preeclampsia symptoms. Despite much attention focused on describing autoantibodies associated with preeclampsia, there is no clue concerning the cell population producing them. CD19(+)CD5(+) B-1a B cells constitute the main source of natural and polyreactive antibodies, which can be directed against own structures. Here, we aimed to identify the B-cell subpopulation responsible for autoantibody production during preeclampsia and to study their regulation, as well as their possible use as markers for the disease. The frequency of CD19(+)CD5(+) cells in peripheral blood of preeclamptic patients is dramatically increased compared with normal pregnant women as analyzed by flow cytometry. This seems to be driven by the high human chorionic gonadotropin levels present in the serum and placenta supernatant of preeclamptic patients versus normal pregnant women. Not only ≈95% of CD19(+)CD5(+) cells express the human chorionic gonadotropin receptor, but these cells also expand on human chorionic gonadotropin stimulation in a lymphocyte culture. Most importantly, isolated CD19(+)CD5(+) cells produce autoantibodies against angiotensin type 1 receptor II, and CD19(+)CD5(+) cells were further detected in the placenta of preeclamptic but not of normal pregnancies where barely B cells are present. Our results identify a B-cell population able to produce pregnancy-pathological autoantibodies as possible markers for preeclampsia, which opens vast diagnostic and therapeutic applications.     

CD4+ and CD56+ acute monoblastic leukemia.

We report here a patient with acute monoblastic leukemia whose leukemia cells had CD4 (T4) and CD56 (NKH-1) antigens, in addition to CD36 (OKM5) antigen. The leukemia cells did not have NK or ADCC activities. They showed no rearrangements of immunoglobulin heavy (IgH) chain and T cell receptor (TCR)-beta chain genes, indicating that the leukemia cells were nonlymphoid. The presence of this case suggests that leukemia cells could be originated from monocytes with NK-associated antigen without IgH or TCR rearrangements.     

CD4+ CD56+ Hematodermic Neoplasm Without Cutaneous Involvement

First evidence of cases of haemophilia dates from ancient Egypt, but it was when Queen Victoria from England in the 19th century transmitted this illness to her descendants, when it became known as the “royal disease”. Last decades of the 20th century account for major discoveries that improved the life expectancy and quality of life of these patients. The history and evolution of haemophilia healthcare counts ups and downs. The introduction of prophylactic schemes during the 1970s have proved to be more effective that the classic on-demand replacement of clotting factors, nevertheless many patients managed with frequent plasma transfusions or derived products became infected with the Human Immunodeficiency Virus (HIV) and Hepatitis C virus during the 1980s and 1990s. Recombinant factor VIII inception has decreased the risk of blood borne infections and restored back longer life expectancies. Main concerns for haemophilia healthcare are shifting from the pure clinical aspects to the economic considerations of long-term replacement therapy. Nowadays researchers’ attention has been placed on the future costs and cost-effectiveness of costly long-term treatment. Equity considerations are relevant as well, and alternative options for less affluent countries are under the scope of further research. The aim of this review was to assess the evidence of different treatment options for haemophilia type A over the past four decades, focusing on the most important technological advances that have influenced the natural course of this “royal disease”.     

CD4＋CD25＋Treg细胞与支气管哮喘

CD4＋CD25＋Treg细胞的主要作用表现为免疫无能性和免疫抑制性,是外周免疫耐受形成机制的主要组成部分。其主要作用机制为分泌抑制性细胞因子（IL-10和TGF-β）、表达细胞表面分子（CTLA-4、GITR等）及Foxp3等。支气管哮喘患者外周血CD4＋CD25＋Treg功能及数量存在异常,这可能是支气管哮喘发病机制之一。糖皮质激素可以通过影响CD4＋CD25＋Treg的状态起到抑制支气管哮喘气道炎症的作用。